These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33906927)
21. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia. Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423 [TBL] [Abstract][Full Text] [Related]
22. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study. Lindberg BF; Nelson I; Ranstam J; Riker DK PLoS One; 2023; 18(1):e0279204. PubMed ID: 36652464 [TBL] [Abstract][Full Text] [Related]
24. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167 [TBL] [Abstract][Full Text] [Related]
25. Does Trypsin Oral Spray (Viruprotect Huijghebaert S; Vanham G; Van Winckel M; Allegaert K Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064793 [TBL] [Abstract][Full Text] [Related]
26. Effect of cyclosporin A on respiratory viral replication in fully differentiated ex vivo human airway epithelia. Bondeelle L; Huang S; Constant S; Clément S; Salmona M; Le Goff J; Bergeron A; Tapparel C Pharmacol Res Perspect; 2024 Oct; 12(5):e1242. PubMed ID: 39210688 [TBL] [Abstract][Full Text] [Related]
27. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report. Clarsund M; Blom U; Gardulf A J Med Case Rep; 2016 Oct; 10(1):302. PubMed ID: 27799071 [TBL] [Abstract][Full Text] [Related]
29. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Hui KPY; Cheung MC; Perera RAPM; Ng KC; Bui CHT; Ho JCW; Ng MMT; Kuok DIT; Shih KC; Tsao SW; Poon LLM; Peiris M; Nicholls JM; Chan MCW Lancet Respir Med; 2020 Jul; 8(7):687-695. PubMed ID: 32386571 [TBL] [Abstract][Full Text] [Related]
30. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Sims AC; Burkett SE; Yount B; Pickles RJ Virus Res; 2008 Apr; 133(1):33-44. PubMed ID: 17451829 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702 [TBL] [Abstract][Full Text] [Related]
32. Viral Interference During Influenza A-SARS-CoV-2 Coinfection of the Human Airway Epithelium and Reversal by Oseltamivir. Cheemarla NR; Watkins TA; Mihaylova VT; Foxman EF J Infect Dis; 2024 May; 229(5):1430-1434. PubMed ID: 37722683 [TBL] [Abstract][Full Text] [Related]
33. Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants. Chiu MC; Li C; Liu X; Song W; Wan Z; Yu Y; Huang J; Xiao D; Chu H; Cai JP; To KK; Yuen KY; Zhou J mBio; 2022 Aug; 13(4):e0194422. PubMed ID: 35938726 [TBL] [Abstract][Full Text] [Related]
34. P80 natural essence spray and lozenges provide respiratory protection against Influenza A, B, and SARS-CoV-2. Zaderer V; Diem G; Posch W; Jakschitz T; Bonn GK; Bellmann-Weiler R; Huber LA; Wilflingseder D Respir Res; 2024 Feb; 25(1):102. PubMed ID: 38419061 [TBL] [Abstract][Full Text] [Related]
35. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection. Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828 [TBL] [Abstract][Full Text] [Related]
36. The Transcriptome Landscape of the In Vitro Human Airway Epithelium Response to SARS-CoV-2. Assou S; Ahmed E; Morichon L; Nasri A; Foisset F; Bourdais C; Gros N; Tieo S; Petit A; Vachier I; Muriaux D; Bourdin A; De Vos J Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569398 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 infection aggravates cigarette smoke-exposed cell damage in primary human airway epithelia. Chen R; Hui KP; Liang Y; Ng KC; Nicholls JM; Ip MS; Peiris M; Chan MC; Mak JC Virol J; 2023 Apr; 20(1):65. PubMed ID: 37041586 [TBL] [Abstract][Full Text] [Related]
38. Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia. Bovard D; van der Toorn M; Schlage WK; Constant S; Renggli K; Peitsch MC; Hoeng J Biochem Biophys Rep; 2022 Mar; 29():101187. PubMed ID: 34931176 [TBL] [Abstract][Full Text] [Related]
39. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer. Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230 [TBL] [Abstract][Full Text] [Related]
40. Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection Gamage AM; Tan KS; Chan WOY; Lew ZZR; Liu J; Tan CW; Rajagopalan D; Lin QXX; Tan LM; Venkatesh PN; Ong YK; Thong M; Lin RTP; Prabhakar S; Wang Y; Wang LF mBio; 2022 Feb; 13(1):e0343621. PubMed ID: 35038898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]